Literature DB >> 30094095

Aryl hydrocarbon receptor activated by benzo (a) pyrene promotes SMARCA6 expression in NSCLC.

Chao Mao1,2, Min Wang1,2,3, Banglun Qian4, Lianlian Ouyang1,2, Ying Shi1,2, Na Liu1,2, Ling Chen1,2, Desheng Xiao5, Xiang Wang4, Ya Cao1,2, Shuang Liu6, Yongguang Tao1,2,4,6, Wenliang Liu4.   

Abstract

Recent studies suggest that individual subunits of chromatin-remodeling complexes generate epigenetically specific signaling in tumorigenicity. The impact of environmental factors on the chromatin-remodeling factor has not been thoroughly elucidated to date. We detected the expression level of SMARCA6 (SWI/SNF2-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 6) in NSCLC (Non-small-cell lung carcinoma) and measured it through quantitative real-time PCR (qRT-PCR) and immunohistochemistry. The effects of BaP on proliferation and cell cycle progression were evaluated using MTT, colony formation and FACS analyses. Tumor growth in vivo was observed in a xenograft model. ChIP and qPCR were performed to validate that SMARCA6 was a potential target of AhR in NSCLC. As a result, BaP increased SMARCA6 expression. Smoking was linked with elevated SMARCA6 expression in NSCLC. BaP promoted cancer progression in vitro and in vivo. ChIP assay confirmed that BaP increases SMARCA6 expression via recruitment of AhR and induces SMARCA6 expression by facilitating AhR translocation to the nucleus. Furthermore, inhibition of AhR expression decreases SMARCA6 expression in NSCLC. Finally, knockdown of SMARCA6 attenuates BaP-induced cancer progression. This study demonstrates that BaP promotes proliferation by activation of AhR, which promotes SMARCA6 expression, and may identify new diagnostic and therapeutic targets in lung cancer.

Entities:  

Keywords:  AhR; BaP; SMARCA6; lung cancer; smoking

Year:  2018        PMID: 30094095      PMCID: PMC6079155     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  48 in total

1.  Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Kah Poh Tan; Bernice Wang; Mingdong Yang; Paul C Boutros; Jane Macaulay; Haibo Xu; Andrew I Chuang; Kazuhiro Kosuge; Mika Yamamoto; Shinichiro Takahashi; Alex M L Wu; Douglas D Ross; Patricia A Harper; Shinya Ito
Journal:  Mol Pharmacol       Date:  2010-05-11       Impact factor: 4.436

2.  SMARCE1 is required for the invasive progression of in situ cancers.

Authors:  Ethan S Sokol; Yu-Xiong Feng; Dexter X Jin; Minu D Tizabi; Daniel H Miller; Malkiel A Cohen; Sandhya Sanduja; Ferenc Reinhardt; Jai Pandey; Daphne A Superville; Rudolf Jaenisch; Piyush B Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-04       Impact factor: 11.205

3.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

4.  Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Authors:  Alban Bessede; Marco Gargaro; Maria T Pallotta; Davide Matino; Giuseppe Servillo; Cinzia Brunacci; Silvio Bicciato; Emilia M C Mazza; Antonio Macchiarulo; Carmine Vacca; Rossana Iannitti; Luciana Tissi; Claudia Volpi; Maria L Belladonna; Ciriana Orabona; Roberta Bianchi; Tobias V Lanz; Michael Platten; Maria A Della Fazia; Danilo Piobbico; Teresa Zelante; Hiroshi Funakoshi; Toshikazu Nakamura; David Gilot; Michael S Denison; Gilles J Guillemin; James B DuHadaway; George C Prendergast; Richard Metz; Michel Geffard; Louis Boon; Matteo Pirro; Alfonso Iorio; Bernard Veyret; Luigina Romani; Ursula Grohmann; Francesca Fallarino; Paolo Puccetti
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

5.  A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

Authors:  Nicholas C D'Amato; Thomas J Rogers; Michael A Gordon; Lisa I Greene; Dawn R Cochrane; Nicole S Spoelstra; Travis G Nemkov; Angelo D'Alessandro; Kirk C Hansen; Jennifer K Richer
Journal:  Cancer Res       Date:  2015-09-11       Impact factor: 12.701

6.  The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells.

Authors:  Elizabeth A Stanford; Zhongyan Wang; Olga Novikov; Francesca Mulas; Esther Landesman-Bollag; Stefano Monti; Brenden W Smith; David C Seldin; George J Murphy; David H Sherr
Journal:  BMC Biol       Date:  2016-03-16       Impact factor: 7.431

7.  Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas.

Authors:  Desheng Xiao; Jun Huang; Yu Pan; Hao Li; Chunyan Fu; Chao Mao; Yan Cheng; Ying Shi; Ling Chen; Yiqun Jiang; Rui Yang; Yating Liu; Jianhua Zhou; Ya Cao; Shuang Liu; Yongguang Tao
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

8.  Chromatin remodeling factor lymphoid-specific helicase inhibits ferroptosis through lipid metabolic genes in lung cancer progression.

Authors:  Yiqun Jiang; Yuchen He; Shuang Liu; Yongguang Tao
Journal:  Chin J Cancer       Date:  2017-10-16

9.  Genome-wide DNA methylation patterns in LSH mutant reveals de-repression of repeat elements and redundant epigenetic silencing pathways.

Authors:  Weishi Yu; Carl McIntosh; Ryan Lister; Iris Zhu; Yixing Han; Jianke Ren; David Landsman; Eunice Lee; Victorino Briones; Minoru Terashima; Robert Leighty; Joseph R Ecker; Kathrin Muegge
Journal:  Genome Res       Date:  2014-08-28       Impact factor: 9.043

10.  EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes.

Authors:  Yiqun Jiang; Chao Mao; Rui Yang; Bin Yan; Ying Shi; Xiaoli Liu; Weiwei Lai; Yating Liu; Xiang Wang; Desheng Xiao; Hu Zhou; Yan Cheng; Fenglei Yu; Ya Cao; Shuang Liu; Qin Yan; Yongguang Tao
Journal:  Theranostics       Date:  2017-07-23       Impact factor: 11.556

View more
  10 in total

Review 1.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

2.  Cancer progression is mediated by proline catabolism in non-small cell lung cancer.

Authors:  Yating Liu; Chao Mao; Min Wang; Na Liu; Lianlian Ouyang; Shouping Liu; Haosheng Tang; Ya Cao; Shuang Liu; Xiang Wang; Desheng Xiao; Ceshi Chen; Ying Shi; Qin Yan; Yongguang Tao
Journal:  Oncogene       Date:  2020-01-07       Impact factor: 9.867

Review 3.  Lymphoid-specific helicase in epigenetics, DNA repair and cancer.

Authors:  Xiangyu Chen; Yamei Li; Karla Rubio; Bi Deng; Yuyi Li; Qinwei Tang; Chao Mao; Shuang Liu; Desheng Xiao; Guillermo Barreto; Yongguang Tao
Journal:  Br J Cancer       Date:  2021-09-07       Impact factor: 9.075

Review 4.  Converging Roles of the Aryl Hydrocarbon Receptor in Early Embryonic Development, Maintenance of Stemness, and Tissue Repair.

Authors:  Hesbon A Zablon; Chia-I Ko; Alvaro Puga
Journal:  Toxicol Sci       Date:  2021-07-16       Impact factor: 4.849

Review 5.  The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis.

Authors:  Lei Zhang; Yiyi Liang; Shifu Li; Fanyuan Zeng; Yongan Meng; Ziwei Chen; Shuang Liu; Yongguang Tao; Fenglei Yu
Journal:  Mol Cancer       Date:  2019-03-09       Impact factor: 27.401

6.  LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer.

Authors:  Rui Yang; Na Liu; Ling Chen; Yiqun Jiang; Ying Shi; Chao Mao; Yating Liu; Min Wang; Weiwei Lai; Haosheng Tang; Menghui Gao; Desheng Xiao; Xiang Wang; Fenglei Yu; Ya Cao; Qin Yan; Shuang Liu; Yongguang Tao
Journal:  J Exp Clin Cancer Res       Date:  2019-06-28

7.  LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis.

Authors:  Li-Ming Xu; Ya-Jing Yuan; Hao Yu; Shuai Wang; Ping Wang
Journal:  J Transl Med       Date:  2022-08-02       Impact factor: 8.440

8.  CYP2S1 is a synthetic lethal target in BRAFV600E-driven thyroid cancers.

Authors:  Yiqi Li; Xi Su; Chao Feng; Siyu Liu; Haixia Guan; Yue Sun; Nongyue He; Meiju Ji; Peng Hou
Journal:  Signal Transduct Target Ther       Date:  2020-09-11

9.  The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor.

Authors:  Lianlian Ouyang; Bin Yan; Yating Liu; Chao Mao; Min Wang; Na Liu; Zuli Wang; Shouping Liu; Ying Shi; Ling Chen; Xiang Wang; Yan Cheng; Ya Cao; Desheng Xiao; Lingqiang Zhang; Shuang Liu; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2020-06-17

10.  AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma.

Authors:  Qing Zhu; Yarui Ma; Junbo Liang; Zhewen Wei; Mo Li; Ying Zhang; Mei Liu; Huan He; Chunfeng Qu; Jianqiang Cai; Xiaobing Wang; Yixin Zeng; Yuchen Jiao
Journal:  Signal Transduct Target Ther       Date:  2021-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.